Company ARPIDA Swiss Exchange

Equities

ARPN

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

Inactive Instrument

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

Apr. 15	Evolva Shareholders Pass Resolutions to Revoke Liquidation, Delisting	MT
Mar. 26	Evolva Secures Temporary Exemption from Listing Rules Amid Liquidation	MT

Evolva Holding SA (Evolva) discovers and provides ingredients for health, nutrition and wellness. Evolva uses biosynthetic and evolutionary technologies to create small molecule compounds and their production routes. The Companyâs nutrition and consumer products include Pomecins, saffron, stevia, vanilla and resveratrol. The Companyâs pharmaceuticals products include EV-077 and EV-035. In pharmaceuticals, the Company focuses on oral, small molecule drugs with application in complications of diabetes and infectious diseases. Pomecins are Evolvaâs compounds. Evolva is focused on two members of the family - Pomecin A and Pomecin B. EV-035 is a bacterial type II topoisomerase inhibitor. Evolva is developing EV-077 for the treatment of diabetic complications. It is an oral, small molecule compound, belonging to a structural class.

CHF in Million	2021	Weight	2022	Weight	Delta
Novel Food, Nutritional and Healthcare Ingredients Product-related 95.5 %	9	92.6 %	15	95.5 %	+62.28%
Research & Development 4.5 %	1	7.4 %	1	4.5 %	-5.01%

CHF in Million	2021	Weight	2022	Weight	Delta
Switzerland 59.2 %	5	50.2 %	9	59.2 %	+85.69%
United States 40.8 %	5	49.8 %	6	40.8 %	+28.75%

Managers	Title	Age	Since
Christian Wichert CEO	Chief Executive Officer	50	22-02-07
Gerhard Lobmaier COO	Chief Operating Officer	55	20-12-31
Astrid Schäfer CTO	Chief Tech/Sci/R&D Officer	51	17-12-31
Doris Rudischhauser IRC	Investor Relations Contact	57	-
Fabienne Gschwind HRO	Human Resources Officer	51	21-02-28
Philipp Frech LAW	General Counsel	45	21-12-31

Members of the board	Title	Age	Since
Stephan Schindler CHM	Chairman	60	20-04-14
Beat In-Albon BRD	Director/Board Member	72	20-04-14
Andreas Pfluger BRD	Director/Board Member	64	22-03-31
Christoph Breucker BRD	Director/Board Member	66	21-03-31
Andreas Weigelt BRD	Director/Board Member	43	22-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	7,232,496	4,693,968 ( 64.90 %)	19,074 ( 0.2637 %)	64.90 %

Name	Equities	%	Valuation
Nice & Green SA 7.554 %	546,199	7.554 %	544 899 CHF
Picard Angst AG 0.0578 %	4,178	0.0578 %	4 168 CHF
DWS CH AG 0.0411 %	2,973	0.0411 %	2 966 CHF
Quorus Vermögensverwaltung AG 0.0111 %	800	0.0111 %	798 CHF
State Street Global Advisors France SA 0.006583 %	476	0.006583 %	475 CHF
LLB Asset Management AG 0.003319 %	240	0.003319 %	239 CHF
Dux Inversores SGIIC SA 0.001245 %	90	0.001245 %	90 CHF
EVOLVA HOLDING SA 0.000968 %	70	0.000968 %	70 CHF

Name	Equities	%	Valuation
EVOLVA HOLDING SA 0.00%	70	0.00%	70 $

Evolva Holding SA

Duggingerstrasse 23

4153, Reinach

+41 61 485 2000

http://www.evolva.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+18.97%	45.34B
LONZA GROUP AG	+41.98%	40.42B
IQVIA HOLDINGS INC.	-10.06%	37.92B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.75B
CELLTRION, INC.	-7.79%	27.71B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.96B
MEDPACE HOLDINGS, INC.	+31.28%	12.44B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research